Company

Scancell Holdings plc

Headquarters: Oxford, United Kingdom

Employees: 25

CEO: Prof. Lindy Gillian Durrant Ph.D.

LSE: SCLP

Market Cap

£99.7 Million

GBP as of Jan. 1, 2024

US$127.0 Million

Market Cap History

Scancell Holdings plc market capitalization over time

Evolution of Scancell Holdings plc market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Scancell Holdings plc

Detailed Description

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Scancell Holdings plc has the following listings and related stock indices.


Stock: LSE: SCLP wb_incandescent

Stock: FSX: SCP wb_incandescent

Stock: OTC: SCNLF wb_incandescent

Details

Headquarters:

John Eccles House

Robert Robinson Avenue Oxford Science Park

Oxford, OX4 4GP

United Kingdom

Phone: 44 1865 338 069